Teenage acne may increase risk of melanoma
the ONA take:
According to a new study published in the journal Cancer, researchers from Brigham and Women's Hospital in Boston, Massachusetts have found an association between teenage acne and melanoma.
For the study, researchers followed 99,128 female nurses from the Nurses' Health Study II cohort for 20 years to investigate the risk of eight cancers.
Results showed that among participants with a history of severe teenage acne, the risk of developing melanoma after adjusting for known risk factors increased. The multivarable--adjusted hazard ratio was 1.44. Those with teenage acne were also more likely to have moles (52.7% versus 50.1%; P < 0.001).
Furthermore, in an independent melanoma case-control study that included 930 cases of melanoma and 1,026 control cases, the association between teenage acne and melanoma was found. In that study, the multivaribale-adjusted odds ratio was 1.27.
Those with teenage acne in this study were also more likely to have moles (55.2% versus 45.1%; P = 0.004). The findings suggest that teenage acne may be a new risk factor for melanoma, but further studies are warranted to confirm this association.
An association between teenage acne and melanoma.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|